HUTCHMED (China) Ltd (HCM) ADR each Representing 0.5 Shares

Sell:$16.10Buy:$16.13$0.78 (5.09%)

NASDAQ:2.20%
Market closed | Prices delayed by at least 15 minutes
Sell:$16.10
Buy:$16.13
Change:$0.78 (5.09%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$16.10
Buy:$16.13
Change:$0.78 (5.09%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

Key people

Weiguo Su
Chief Executive Officer, Chief Scientific Officer, Executive Director
Chig Fung Cheng
Chief Financial Officer, Executive Director
Karen Jane Atkin
Chief Operating Officer, Executive Vice President
Hong Chen
Executive Vice President and Chief Commercial Officer, China
Ming Shi
Executive Vice President, Head - Research and Development and Chief Medical
Zhenping Wu
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Kin Hung Lee
Senior Vice President - Corporate Management and Communications
Qingmei Wang
Senior Vice President - Business Development and Strategic Alliances
Charles George Rupert Nixon
Group General Counsel
Dan Eldar
Non-Executive Chairman of the Board
Edith Shih
Non-Executive Director, Company Secretary
Ling Yang
Non-Executive Director
Renu Bhatia
Independent Non-Executive Director
Paul Rutherford Carter
Senior Independent Non-Executive Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Hong Kong
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US44842L1035
  • Market cap
    $2.57bn
  • Employees
    1,970
  • Shares in issue
    871.60m
  • Exchange
    Hong Kong Stock Exchange
  • Index
    TR Equity Hong Kong Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.